Fragment-based Drug Discovery Market is projected to increase value US$0.4 bn to US$1.2 bn During forecast period 2016-2023
In this research study, the global fragment-based drug discovery market has been evaluated on the basis of the service component and end user. Based on service component, the market is broadly segmented into fragment screening and fragment optimization. Of these, the fragment screening segment occupied the leading position in 2014.The report further classifies this segment into biophysical techniques and non-biophysical techniques. The biophysical techniques segment is then categorized into differential scanning fluorimetry (DSF) assay (Thermal Shift), nuclear magnetic resonance (NMR) spectroscopy, x-ray crystallography, isothermal titration calorimetry (ITC), fluorescence polarization (FP), biolayer interferometry, surface plasmon resonance, capillary electrophoresis, mass spectrometry, and biochemical assays.
Download Free Research Report Brochure PDF: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4741
Biopharmaceutical companies, academic and research institutions, and CROs are the major end users of fragment-based drugs discovery services. In 2014, biopharmaceutical companies emerged as the biggest fragment-based drugs discovery services user and held a share of 46% in the overall market.
The report also analyzes the global market for fragment-based drug discoveries on the basis of its regional segmentation. According to the report, North America led the global market in 2014. The presence of pharmaceutical companies in a large number in the U.S. was the main factor behind the dominance of North America among all the regional markets for fragment-based drug discoveries including Latin America, Europe, Asia Pacific, and the Rest of the World.
The increasing research and development activities for fragment-based drug discoveries are projected to drive the North America fragment-based drug discovery market in the coming years, states the research report. However, analysts expect the fragment-based drug discovery market in Asia Pacific to exhibit the highest growth over the forecast period.
The rise in research and development activities for drug discovery in various emerging nations in Asia, together with the increasing demand for advanced medical and healthcare infrastructure, is likely to drive the growth of the Asia Pacific market for fragment-based drug discoveries, notes the study.
The global fragment-based drug discovery market is highly fragmented in nature, states the research report. Sygnature Discovery, Kinetic Discovery Ltd., Emerald BioStructures Inc., Evotec AG, Crown Bioscience Inc., Sprint Bioscience, Beactica AB, Astex Pharmaceuticals, Proteros Fragments GmbH, Charles River Laboratories International Inc., Structure Based Design Inc., and Alveus Pharmaceuticals Pvt. Ltd. are the major market participants mentioned in this study.